Plus Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $26.3M
- Price
- $3.82
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.79%
- Volume
- 84.1K
Quote data as of 5:23 AM ET
About
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Quick stats
Shares outstanding6.9M
Computed float6.7M
Float sourceUnknown
Cash runway (months)-1.5
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001095981
AI Summary
AI-generated14d agomajorbullishpartnershipPlus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Plus Therapeutics' subsidiary CNSide Diagnostics signed a national coverage agreement with Elevance Health effective May 1, 2026.
The deal covers approximately 45.4 million people, bringing total contracted coverage for the CNSide CSF TCE assay to 126 million people.
Since 2020, over 11,000 tests have been performed across more than 120 U.S. cancer institutions, showing 92% sensitivity and 95% specificity.